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Nanogels (NGs) are three dimensional networks composed of hydrophilic or 
amphiphilic polymer chains, allowing for effective and homogeneous encapsulation of 
drugs, genes or imaging contrast agents for biomedical applications. Polyethylenimine (PEI), 
possessing sufficient positively charged amine groups, is an ideal platform for NG 
development. In this study, we synthesized PEI-based NGs loaded with both MR contrast 
agent ultrasmall iron oxide (Fe3O4) nanoparticles (NPs) and the anticancer drug doxorubicin 
(DOX) for tumor theranostics.  
The synthesis of PEI-based NGs was first carried out by an inverse mini-emulsion 
(water-in-oil, W/O) crosslinking strategy. Secondly, the NGs were conjugated with 
ultrasmall Fe3O4 NPs which was performed via a hydrothermal method through 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) chemistry. Then the amine 
groups of the NGs were acetylated by acetic anhydride. The formed PEI-based NGs possess 
good dispersibility and cytocompatibility. The drug release profile was studied, as well as 
the impact of the environmental pH on the release rate of DOX. Results proved that the 
hybrid NGs facilitated a sustained release of DOX with a higher release rate under acidic pH. 
Furthermore, in vitro studies showed that Fe3O4/PEI-Ac NGs had no cytotoxicity towards 
4T1 tumor cells, unlike Fe3O4/PEI-Ac NGs/DOX complexes and Free DOX. The PEI-based 
NGs presented significantly enhanced r1 relaxivity of 2.29 mM
-1s-1 when compared to free 
ultrasmall Fe3O4 NPs (1.15 mM
-1s-1), as well as excellent drug loading efficiency (51.4%). 
Strikingly, the NGs presented enhanced T1 MR imaging ability and a high therapeutic 
efficacy towards cancer cells in vitro and a xenografted tumor model in vivo. 
 









Os nanogéis (NGs) são redes tridimensionais compostas por cadeias poliméricas, 
hidrofílicas ou anfifílicas, que permitem o encapsulamento efetivo e homogéneo de fármacos, 
genes ou agentes de contraste para aplicações biomédicas. A polietilenimina (PEI), por possuir 
muitos grupos amina carregados positivamente, constitui uma plataforma ideal para o 
desenvolvimento de NGs. Neste estudo, sintetizaram-se NGs à base de PEI, nos quais se 
incorporaram nanopartículas de óxido de ferro (Fe3O4) e também o fármaco anticancerígeno 
doxorubicina (DOX) com vista ao tratamento e simultâneo diagnóstico de tumores. 
Em primeiro lugar, a preparação dos NGs foi levada a cabo através de um processo de 
reticulação de mini-emulsão inversa (água em óleo). De seguida, os NGs foram conjugados 
com nanopartículas de Fe3O4 usando um método hidrotérmico e a estratégia de síntese química 
com base na 1-etil-3-(3-dimetilaminopropil)carbodiimida (EDC). Seguidamente, os grupos 
amina foram acetilados usando anidrido acético, obtendo-se os produtos finais (Fe3O4/PEI-Ac 
NGs). Os NGs assim formados mostraram possuir uma boa dispersibilidade e 
citocompatibilidade. A velocidade de libertação da DOX a partir dos NGs foi estudada, assim 
como o impacto do pH nesse processo. Os resultados mostraram haver uma libertação 
sustentada do fármaco que atinge velocidades superiores a valores ácidos de pH. 
Adicionalmente, estudos realizados in vitro com a linha celular tumoral 4T1 mostraram que 
os Fe3O4/PEI-Ac NGs não são citotóxicos, ao contrário do que acontece com os complexos 
Fe3O4/PEI-Ac NGs/DOX e a DOX livre. Os NGs preparados apresentam uma relaxividade r1 
significativamente aumentada (2.29 mM-1s-1) comparativamente com as nanopartículas de 
Fe3O4 livres (1.15 mM
-1s-1), bem como uma excelente eficiência de encapsulamento de DOX 
(51.4%). Surpreendentemente, os nanogéis apresentam uma capacidade aumentada para 
imagiologia de ressonância magnética T1 e uma elevada eficácia terapêutica, quer in vitro 
usando células tumorais, quer num modelo de tumor (xenoenxerto) in vivo. 
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CHAPTER 1 – INTRODUCTION 
 
 
1.1 Nanogels as a nanoplatform for biomedical applications 
 
In recent years, scientists and researchers have been shedding light on nanomaterials as 
cancer diagnostic agents and drug delivery carriers. Nanomaterials, such as nanotubes1,2, 
spherical micelles3, quantum dots4,5, nanofibers6 and nanogels (NGs)7, may exhibit intriguing 
biocompatibility, substantial chemical flexibility and long blood circulation time, rendering 
them with greater advantages in intracellular and extracellular milieu. Among these most 
studied biomedical materials, NGs have been widely used due to their prominent 
biocompatibility8,9, biodegradability10, stimuli-responsiveness, high drug loading efficiency and 




NGs are three-dimensional (3D) networks of hydrophilic or amphiphilic polymer chains 
with massive amounts of internal cavities. The linkage between polymeric chains in the NGs 
could be covalent bonds or physical interactions, such as ionic crosslinking, hydrogen bonding, 
van der Waals interactions and electrostatic interactions, etc. Several preparation methods, such 
as electrostatic complexation13,17, inverse emulsion18, and double emulsion19, have been explored to 
produce smart NGs. NGs, possessing flexible chemical architectures, can be designed as smart 
nanomaterials with sensitivity to pH20,21, temperature22 and photo-thermal variations23. Also, the 
networks in the NGs can be used to mimic extracellular matrix environments and encapsulate 
labile drugs and genes. Due to their similar properties to human tissues and excellent 
biocompatibility, NGs are perfect platforms for biomedical applications in drug delivery, gene 





1.1.2  Polyethylenimine 
 
Polyethylenimine (PEI), one kind of amine-rich polymer, is widely used in controlled drug 
delivery, gene therapy, antimicrobial agents and biomedical imaging25. PEI can be divided into 
two types (linear and branched types) and its molecular weight may vary. The amine groups of 
PEI provide substantial opportunities to load different organic and inorganic materials for 
biomedical applications. For example, the amine functionalities of PEI can be used to 
covalently couple with biomolecules. Additionally, pH-sensitive PEI is suitable for controlled 
drug release. Moreover, polymeric PEI is capable of binding with negatively charged 
molecules, such as DNA, RNA and proteins for tissue engineering and gene therapy25. It has 
been suggested that the mechanism of antibacterial effect of PEI is related to the electrostatic 
interactions between positively charged PEI and negatively charged bacterial cell walls26. 
However, the cationic properties of PEI can lead to serious cytotoxicity to living cells, which 
limits further potential utilization in biomedical areas. As such, methods for reducing its 
cytotoxic behavior, which do not drastically affect its functionalities, are highly demanding.  
Recently, great progress has been made in developing PEI-based NGs with cationic 
characteristics and low cytotoxicity. Apart from being a main material to synthesize NGs, PEI 
can also be used to modulate the surface potential of nanoparticles and allow combination with 
plasmid DNA. The advances in the development of PEI-based NGs will be presented, including 





Figure 1. Scheme showing the possible chemical structures of PEI and examples of their biomedical applications 
in gene delivery, drug delivery and bioimaging. Adapted from ref. 19, 27 Copyright 2018 Elsevier Ltd. 
 
1.2 The synthesis methods of PEI-based NGs 
 
Various methods, such as electrostatic complexation13-17, inverse-emulsion18,28,29, self-assembly 
of biopolymers10,30 and precipitation polymerization method20,31,32 can be used to synthesize NGs. 
With these methods mentioned above, PEI is able to form NGs with large internal cavities and 
improved dispersion and biocompatibility. Current synthesis methods used for the preparation 
of PEI-based NGs can be divided into two types: 1) PEI as a base material to form NGs via a) 
electrostatic interaction and b) crosslinking in a water-in-oil emulsion; 2) PEI as a crosslinker 





Figure 2. (a) Schematic drawing of tannic acid (TA)/PEI polyplex NGs formed via electrostatic interaction. 
Reproduced with permission33. Copyright 2016, Elsevier Ltd. (b) Synthetic procedure to obtain biohybrid NGs via 
crosslinking in W/O emulsion. Reproduced with permission34. Copyright 2016, American Chemical Society. (c) 
Schematic illustration of the formation of PEI-Fe3O4 NPs and AG/PEI- Fe3O4 NGs. Reproduced with permission35. 






1.2.1 Electrostatic interaction 
 
The electrostatic self-assembly of NGs involves controlled aggregation of hydrophilic PEI 
via its cationic amine surface with negatively charged polymers. Generally, the preparation is 
conducted under mild conditions in aqueous environment. Therefore, the electrostatic 
interactions between PEI and negatively polymers allow encapsulation of various biomolecules 
inside the NGs. Sahiner et al. reported the biodegradable NGs, which have been synthesized by 
the electrostatic interaction between the phenolic groups of tannic acid (TA) and the positively 
charged amine groups of PEI33. In the preparation of the TA-PEI NGs, they first dissolved PEI 
in Triton X100/gasoline medium under constant stirring, then mixed with the water solution of 
TA with the weight ratio of 1:1. The reaction was stopped after 15 min. After precipitation in 
acetone and being centrifuged at 10000 rpm at room temperature, TA-PEI NGs were obtained. 
The formed NGs demonstrated highly antioxidant and antimicrobial properties (Figure 2a).  
 
1.2.2 Water-in-oil emulsion 
 
Water-in-oil emulsion can also be called as inverse emulsion. The major difference 
distinguishing water-in-oil emulsion from other emulsion methods is that the water phase is 
mixed in the oil phase during emulsification. Water-in-oil emulsion provides a new strategy to 
control the size of the NGs. In this method, PEI determines the chemical properties of the 
formed NGs, while the reaction conditions decide their physical properties. Peng et al. 
synthesized NGs by crosslinking between poly(N-vinylpyrrolidone) (PVP) and PEI in water-
in-oil emulsion. The aqueous phase had PVP and PEI in potassium phosphate (Kpi) buffer and 
the organic phase consisted of span80 and toluene (Figure 2b) to form the NGs in water-in-oil 
emulsion34. In this study, the polymeric NGs crosslinked by PEI showed a spherical morphology 




1.2.3 PEI as a crosslinker 
 
In addition to the physical interaction methods mentioned above, crosslinking of polymer 
chains provides various opportunities to produce NGs36. Sun et al. reported the fabrication of 
magnetic alginate (AG) NGs using PEI-coated iron oxide (Fe3O4) nanoparticles (PEI-Fe3O4 
NPs) as a crosslinker35. They found that AG/PEI-Fe3O4 NGs were water dispersible, colloidally 
stable and biocompatible. When compared with PEI-Fe3O4 NPs, AG/PEI-Fe3O4 NGs showed 
higher cancer cell uptake ability due to the softness and fluidity of the NGs (Figure 2c). 
Similarly, Zhu et al. utilized -polyglutamic acid (-PGA) as an alternative and synthesized -
PGA/PEI-Fe3O4 NGs37. In these studies, the carboxyl groups of -PGA or AG were activated 
by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), followed by a 
double emulsion process to generate the -PGA or AG NGs. Then, through a dehydration 
condensation reaction between the carboxyl groups of -PGA or AG and the amine groups of 
PEI-coated Fe3O4 NPs, the final NG products were formed.  
 
1.3 Biomedical applications of the PEI-based NGs 
 
1.3.1 Gene therapy 
 
Gene therapy can be defined as the transfer of genetic material into specific cells for 
disease treatment. It is an effective approach to introduce new genes or replace deficient genes 
within affected cells. Gene therapies are flourishing around many applications, like 
cardiovascular and infectious diseases, as well as cancer therapy38. For these applications, a 
high level of the expressed gene is crucial. Gene delivery vehicles can be categorized as 
recombinant viruses and synthetic vectors. In the process of gene transfection, viruses have 
attracted wide attention for their high transfection efficiency. However, severe side effects of 




with viral vectors, non-viral vectors are relatively safe, exerting much lower cytotoxicity and 
immunogenicity, and are easier to be used and produced. 
PEI, one of the most effective non-viral gene vectors, has been used over the last two 
decades. Due to the excellent performance of PEI in gene transfection, researchers have applied 
PEI-containing NGs in gene delivery27,38-58. In general, vectors like PEI-based NGs bind DNA 
or RNA electrostatically, condensing the genetic materials into particles within hundreds of 
nanometers, protecting the genes and mediating effective cellular uptake.  
For gene transfection, both plasmid and siRNA are frequently used as gene drugs. Qian 
and coworkers firstly reported heparin-PEI NGs that can be used to transfer the plasmid DNA 
expressing vesicular stomatitis virus matrix protein (pVSVMP)38. These NGs prevent DNA or 
RNA from being degraded in the transfection process, overcoming a huge problem in gene 
therapy. The same authors constructed pDNA encoding interleukin-15 (IL15) and used heparin-
PEI NGs as a vector to deliver the pDNA for cancer therapy application. After the malignant 
melanoma (B16) and colon carcinoma (CT26) were treated with heparin-PEI NGs/pDNA 
polyplexes, the lung metastasis was significantly inhibited with low level of systemic toxicity59. 
In further work, heparin-PEI NGs were used as carriers to deliver the heparan sulfate 6-O-
endosulfatase 1 gene that can be used to inhibit tumorgenesis60,61. To further enhance gene 
delivery efficiency, the same group developed a new gene delivery system of PEI-
RRRRRRRR(R8)-heparin (HPR) NGs. In their work, heparin and cell penetrating peptide R8 
were grafted on PEI with low molecular weight62. The formed HPR/pDNA NGs delivered the 
plasmid DNA encoding human TNF-related apoptosis ligand (phTRAIL) to HCT-116 cells to 
induce cell apoptosis. In addition, HPR/phTRAIL displayed antitumor capability towards the 
abdominal metastatic colon carcinoma model, showing a promising future for gene therapy. 
PEI (Mw = 25 kDa) has a perfect performance in neutralizing and condensing negatively 




based NGs formed with a large Mw PEI have high cytotoxicity, immunogenicity and slow 
clearance rate 63,64, and the cargos loaded with gene and drug are more difficult to be released 
inside tumor cells65,66. Considering these situations, Li et al. covalently conjugated PEI (with a 
low Mw of 1.8 kDa) with dextrin via a disulfide bond to form bioreduction-responsive NGs 
(dextrin NGs, denoted as DSP) for Bcl2 siRNA delivery. Using this system, they achieved a 
controlled release of Bcl2 siRNA into the cancer cells27. They showed that DSP/siRNA labelled 
with Cy5 displayed the strongest fluorescence intensity after 12 h post injection. Furthermore, 
DSP/Bcl2 siRNA significantly suppressed Bcl2 protein expression compared with control 
group (Figure 3). 
 
Figure 3. (a) Schematic illustration of reduction-sensitive DSP for siRNA delivery. (b) In vivo 
imaging of DSP/siRNA. (c) In vitro apoptosis analysis and in vivo tumor suppression study. Reprinted 
from ref.27 Copyright 2018 Elsevier B.V. 
 
 In a different approach, Costa et al. formulated photodegradable PEI-based NGs, 
allowing for controlled release of different plasmids (pVAX1-LacZ and pcDNA3-FLAG-p53) 




their study, they found that ethylene glycol ethers photooxidize in the presence of sunlight, so 
they used ethylene glycol diglycidyl ether as a crosslinker to confer photodegradable ability to 
the NGs42. PEI NGs condense and stabilize plasmid DNA to form complexes38,67. In vitro 
anticancer assay data revealed that the synergistic tumoral treatment through pcDNA3-FLAG-
p53 gene and anticancer drug significantly suppressed the viability of cancer cells.  
Dimde et al. reported a pH-sensitive NG platform for gene delivery using pH-cleavable 
dendritic polyglycerol-amines (dPG) and low molecular-weight PEI-acrylamide (600 Da) to 
encapsulate siRNA40. These tailor-made NGs were formed through thiol-Michael 
nanoprecipitation method. The incorporation of pH-sensitive benzacetal-moieties inside the NG 
network enables the controlled intracellular release of the cargo. In vitro GFP-siRNA (green 
fluorescent protein) transfection assay showed that this network could silence up to 71% GFP 
expression in HeLa cells.  
 
1.3.2 Drug delivery 
 
NGs are important vehicles in drug delivery due to their reduced clearance rate and longer 
retention time. Normally, small drug molecules have a short circulation time in the serum and 
can be cleared from body rapidly. As such, NGs can be excellent drug carriers to increase drug 
concentration and prolong drug retention time in vivo68. In addition, NGs can control the drug 
release rate through their network mesh size and molecular interactions, such as electrostatic 
and covalent interactions69. Through functionalization, they can locally release drugs and 
reduce off-target treatment and side effects. Moreover, NGs can entrap hydrophobic and 
hydrophilic drugs and release more than two drugs within one system. NGs display a favorable 





Generally, drugs can be incorporated into a NG network by physical encapsulation, 
covalent conjugation, and controlled self-assembly. On the other hand, drugs can be released 
from the NGs via (a) gradual diffusion, (b) network degradation, (c) variation in pH conditions 
(or other environmental stimuli, such as temperature, enzyme, etc.), (d) ion displacement, and 
(e) external energy stimulation  (Figure 4)70.  
 
Figure 4. Drug released from NGs in different ways. Reprinted from ref.70 Copyright 2009 Wiley-VCH 
Verlag GmbH & Co. KGaA, Weinheim  
 
Vinogradov et al. reported cytotoxic nucleoside analog drug delivery, which is based on 
polyplex NGs (PEI-PEG NGs)15,69,71,72. They explored various methods to synthesize PEI-PEG 
NGs and fabricated an excellent drug and gene delivery system. In this case, PEI-PEG NGs 
were used to spontaneously encapsulate negatively charged oligonucleotide (ODN), forming a 
stable aqueous dispersion of polyelectrolyte complexes. They verified that ODN can be 
effectively transported across the blood-brain barrier (BBB) independently of the specific 
targeting agent (transferrin or insulin) linked to PEI-PEG NGs. The formed NGs conferred 
resistance to the ODN against degradation from the immune system.69 The drug loading 
efficiency of the synthesized NGs was as high as 33%. This formulation could be a promising 





In another work, Li et al. reported the preparation of Pluronic F127 micelles crosslinked 
by PEI to form F127/PEI NGs, and incorporated with the hydrophobic anticancer drugs 
paclitaxel (PTX) and 10-hydroxycamptothecin (HCPT)73. The F127/PEI NGs were synthesized 
by emulsification/solvent evaporation method. The drug and lyophilized empty NGs were 
dissolved in chloroform. After rotary vacuum evaporation, further lyophilization, hydration 
with 2-[4-(2-Hydroxyethyl)-1-piperazinyl]ethanesulfonic acid(HEPES)-buffered saline and 
filtration through nylon filter, the filtrate was lyophilized to get the drug-loaded F127/PEI NGs. 
The drug-loaded F127/PEI NGs showed a continued in vitro drug release profile compared with 
the free drug. According to the cytotoxicity results, drug-loaded NGs exhibited much higher 
cytotoxicity against cancer cells in vitro than free drugs. The drug-loaded NGs presented greater 
stability, better cellular uptake and increased solubility73. 
Wu et al. used thiolated AG and stearoyl-derivatized PEI to form dual-sensitive (pH-
sensitive and redox-sensitive upon exposure to glutathione (GSH)) fluorescent branched AG-
PEI copolymer (bAPSC) NGs74. bAPSC NGs were synthesized from branched PEI and AG 
through an amidation reaction using EDC/NHS. The bAPSC NGs were used to load DOX 
through ultrasonication and aqueous dialysis methods. The bAPSC NGs had a size of around 
130 nm and negative surface potential (as shown in Figure 5a). Through characterization by 
UV-vis spectroscopy, the drug loading efficiency and drug loading content of the DOX was 
calculated to be 11.2% and 25.9%, respectively. The results of release kinetic studies (as shown 
in Figure 5b) showed that the bAPSC NGs were pH-sensitive and GSH-sensitive, and the drug 
could be rapidly released under acid pH condition in the presence of GSH. Cell viability assays 
(as shown in Figure 5c) showed that the bAPSC NGs/DOX displayed less cytotoxicity than 





Figure 5. (a) TEM and SEM images of DOX-loaded bAPSC NGs. (b) In vitro drug release from DOX-
loaded bAPSC NGs (left); In vitro toxicity assay of HeLa cells incubated with DOX and DOX-loaded 
bAPSC NGs (right). Reprinted from ref.74 Copyright 2017 Multidisciplinary Digital Publishing Institute 
AG. 
 
1.3.3 Molecular Imaging 
 
Recently, various nanomaterials have been developed for early-stage detection of cancer 
with different imaging techniques75,76, such as magnetic resonance (MR)77-79, computed 
tomography (CT)80-82, positron emission computed tomography (PET)83-85, single-photon 
emission computed tomography (SPECT)86-88, photoacoustic imaging (PAI)89-90. Each imaging 
technique has its advantages and cannot be completely replaced by the other technologies. 
Contrast agents (CAs) are indispensable auxiliary tools for efficient and accurate diagnosis in 
molecular imaging. For instance, gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) 
can be used for MR imaging91-92, Omnipaque for CT imaging93, fludeoxyglucose (18F-FDG) for 
PET imaging94-95. Clinical applications of these contrast agents are limited due to their renal 




show significant improvements in imaging performance.  
CT imaging possesses great advantages in spatial resolution, high density resolution, easy 
operation and cost effectiveness. In CT imaging, contrast agents are indispensable to improve 
X-ray attenuation and further locate disease areas. Shi and coworkers synthesized Au NP-
loaded γ-PGA NGs by a double emulsion approach96. Through the in-situ EDC-mediated 
crosslinking of the amine groups of PEI-entrapped Au NPs and carboxyl groups of γ-PGA, the 
NGs were formed with a size of 108.6 ± 19.14 nm. The formed γ-
PGA−[(Au0)200−PEI·NH2−mPEG] NGs presented greater X-ray attenuation when compared to 
commercial iodinated small molecular contrast agents (e.g., Omnipaque). Furthermore, the 
cellular uptake of the formed NGs was more significant than γ-PGA-stabilized single Au NPs 
at the same concentration. The formed NGs presented a great potential to be employed as 
efficient contrast agents for CT imaging of cancer cells in vitro and in a xenografted tumor 
model in vivo (Figure 6).  
 
Figure 6. (a) CT images and (b) tumor CT values of the nude mice bearing xenografted HeLa tumor at 
different time points postintravenous injection of the γ-PGA-[(Au0)200-PEI.NH2-mPEG NGs. Reprinted 





To promote the use of NGs for other imaging applications, the Shi group reported the 
preparation of PEI-crosslinked AG NGs incorporated with Fe3O4 NPs for MR imaging 
applications35. Firstly, PEI-stabilized Fe3O4 NPs were synthesized via a hydrothermal method. 
Then, the carboxyl groups of AG were activated by EDC. After double emulsion to form the 
AG NGs, PEI-stabilized Fe3O4 NPs were used as a crosslinker between the amine group of PEI-
Fe3O4 NPs and carboxyl groups of AG NGs. The final hybrid NGs presented good water 
dispersibility, colloidally stability, and were easy uptaken by tumor cells. This kind of hybrid 
NGs could enhance T2-weighted MR imaging of cancer cells in vitro and in a xenografted tumor 
model in vivo. Similarly, in another work35, the authors were able to incorporate PEI-stabilized 
Fe3O4 NPs synthesized via a mild reduction method within PGA NGs to have an r2 relaxivity 
of 170.87 mM-1s-1 for MR imaging of tumors. 
For T1-weighted MR imaging
97,98, Sun et al. formed AG-based NGs containing PEI-
Mn3O4 NPs using the same approach
97. The size of the formed NGs was about 141.6 nm. The 
hybrid NGs displayed an r1 relaxivity (26.12 mM
-1s-1), which is 19.5 times higher than that of 
PEI-Mn3O4 NPs. Within the nanogels, the incorporated Mn3O4 NPs are able to be used for MR 
imaging in a xenografted tumor model in vivo with significantly better sensitivity than the 
PEI.Ac-Mn3O4 NPs. 
To further promote the use of NGs for dual mode CT/MR imaging, the Shi group used PEI 
as a scaffold that was first modified with PEG for entrapment of Au NPs and surface Gd 
chelation. Then the functionalized PEI was used as crosslinker to prepare hybrid AG/PEI-Au-
Gd NGs19. The formed AG/PEI-Au-Gd NGs showed a higher r1 relaxivity (9.16 mM
-1 s-1) than 
acetylated PEI-Au-Gd NPs (PEI.Ac-Au-Gd NPs) and the clinical MR contrast agent 
(Magnevist), and greater X-ray attenuation performance than conventional iodinated CT 
contrast agents (Omnipaque). Furthermore, the NGs are more prone to be taken up by cancer 




of cancer cells in vitro as well as in a xenografted tumor model in vivo (Figure 7). 
 
 
Figure 7. In vivo T1-weighted MR images (a), MR SNR (b), CT images (c), and CT values (d) of 
xenografted HeLa tumor-bearing mice before and at different time points post intravenous injection of 
the AG/PEI-Au-Gd NGs. Reprinted from ref.52 Copyright 2018 The Royal Society of Chemistry. 
 
1.4 Objectives and General strategy of this thesis 
 
The main goal of this study was to synthesize PEI-based NGs loaded with both MR 
contrast agent ultrasmall Fe3O4 NPs and anticancer drug DOX as a tumor theranostic 
nanoplatform. As shown in Figure 8, firstly, ultrasmall Fe3O4 NPs were synthesized through a 
solvothermal method. Secondly, the PEI NGs were prepared via a mini-inverse emulsion 
method and crosslinked by N,N′-methylenebisacrylamide (BIS) via Michael addition. After that, 
the carboxyl groups of the ultrasmall Fe3O4 were activated by EDC/NHS, and then conjugated 
with the amine groups on the PEI NG surface. Then, the rest of amine groups of NGs were 




NGs/DOX complexes were obtained. The release kinetics of DOX and the r1 relaxivity of the 
NGs were also investigated. After synthesis and the characterization of the final product, in 
vitro and in vivo studies were performed to investigate the therapeutic efficacy and imaging 
capability of the final product. 4T1 tumor cells and BALB/c nude mice were used. 
 



















































CHAPTER 2 – MATERIALS AND METHODS 
 
1.5 Materials and reagents 
Branced PEI (bPEI; Mw = 2.5k), BIS and Span® 80 were purchased from SIGMA-
ALDRICH (St. Louis, MO). The EDC and NHS were purchased from J&K Scientific Ltd. 
(Shanghai, China) Triethylamine, acetic anhydride and toluene were purchased from 
Aladdin Ltd. (Shanghai, China). All other chemicals were obtained from Suzhou Yacoo 
Science Co., Ltd. (Suzhou, China). Unless otherwise stated, all chemicals were used as 
received. Cell culture dishes were from Corning Incorporation (New York, NY). 4T1 cells 
were from Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of 
Sciences (Shanghai, China). Dulbecco’s modified Eagle medium (DMEM) and antibiotic 
and antimycotic (AA) 100x solution were purchased from Hangzhou Jinoo Biomedical 
technology Co. Ltd. (Hangzhou, China). Fetal bovine serum (FBS) and trypsin were 
purchased from Gibco BRL (Gaithersburg, MD). Water used in all experiments was purified 
using a MilliQ Plus185 water purification system (Millipore Bedford, MA) and presented a 
resistivity higher than 18.2 MΩ.  
 
1.6 Synthesis of Fe3O4/PEI-Ac NGs 
 
Synthesis of citrate-stabilized Fe3O4 NPs. Ferric chloride anhydrous (FeCl3, 324.4 
mg) was dissolved in 20 mL of diethylene glycol. After ferric chloride was completely 
dissolved, sodium citrate (235.5 mg) was added under stirring. After the sodium citrate was 
completely dissolved, the solution was put into a water bath at 80 ℃ for 120 min. At the end 
of the reaction, the solution was cooled down to 55 ℃, and sodium acetate (656 mg) was 
then added to the mixture solution under stirring to form a transparent solution, which was 
transferred to the high temperature and high-pressure reactor. The reaction in the reactor was 
conducted in an oven at 200 ℃ for 4 h. After the reaction was completed, the product was 
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cooled down to room temperature, centrifuged and purified by washing and redispersed with 
ethanol. Ultrasmall Fe3O4 NPs were formed by lyophilization of the purified product.  
Synthesis of PEI NGs. Span® 80 (1.2 g) was dissolved in toluene (60 mL) under 
stirring at room temperature for 30 min. bPEI (272 mg) and BIS (32 mg) were dissolved in 
5 mL of water, dropwise added in the above solution under stirring for 120 min. 
Ultrasonication was used to achieve emulsification. After that, triethylamine (TEA) as a 
catalyst was added into solution to initiate PEI crosslinking. The mixture solution was stirred 
overnight. At the end of the reaction, the NGs were collected by centrifugation (13 000 rpm, 
15 min) and redispersion in methanol for 3 times to remove toluene. After that, the product 
was purified by dialysis against water using a dialysis membrane with a molecular weight 
cut-off (MWCO) of 8000-14000 for 3 days. 
Synthesis of Fe3O4/PEI NGs. The ultrasmall Fe3O4 NPs (50 mg) synthesized were 
dispersed in water (5 mL) and their surface carboxyl groups were activated by EDC/NHS 
(EDC mass = 75 mg, NHS mass = 45 mg). The mixture solution was dropwise added into 
the solution of PEI NGs (250 mg, 25 mL) under stirring overnight. The product was collected 
through centrifugation (13000 rpm, 15 min) and redispersed in water for 3 times. Then the 
product was purified by dialysis against water using a dialysis membrane (MWCO = 8000-
14000) for 3 days. After that, the Fe3O4/PEI NGs were obtained, which were stored in water 
at 4 ℃. 
Synthesis of Fe3O4/PEI-Ac NGs. The Fe3O4/PEI NGs were acetylated by acetic 
anhydride. The triethylamine (134.1 μL) as a catalyst was dropwise added into the solution 
of the Fe3O4/PEI NGs (20 mg, 2 mL) under stirring for 30 min. Then acetic anhydride (75.9 
μL) was added into the mixture solution under stirring overnight. The product was purified 
by membrane dialysis (MWCO = 8000-14000) against water for 2 days, and then were stored 
at 4 ℃. 
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Drug loading within Fe3O4/PEI-Ac NGs. The Fe3O4/PEI-Ac NGs were centrifuged 
(13000 rpm) and redispersed in PBS (pH = 7.4). Doxorubicin hydrochloride was dissolved 
in water, and then dropwise added into the solution of Fe3O4/PEI-Ac NGs. The mixture 
solution was stirred overnight in the dark. The final product was collected by centrifugation 
(13000 rpm) and stored in the dark at 4 ℃. 
 
1.7 Characterization of the Fe3O4/PEI-Ac NGs 
 
Thermal gravimetric analysis (TGA): Ultrasmall Fe3O4 NPs, Fe3O4/PEI NGs and 
Fe3O4/PEI-Ac NGs was analyzed using a TG209F1 Thermal Gravimetric Analyzer 
(NETZSCH, Selb, Germany). All samples (5ml) were lyophilized to powder before 
measurements. The samples were then heated from room temperature to 900℃ at the rate 
of 20℃/min under nitrogen protection.  
Hydrodynamic size and zeta-potential: The starting materials and the products from each 
step were measured using a Nano-ZS (Malvern, Malvern, UK). All the materials and 
products were dissolved in water. The concentration of the solutions was approximately 
10mg/mL. 
UV-vis spectra: The spectra were recorded using a Perkin-Elmer Lambda 25 UV-vis 
spectrophotometer (Boston, MA). All the materials and products were dissolved in water. 
The concentration used in the UV-vis spectra analysis was dependent on the specific 
situation. 
Atomic force microscope (AFM): The AFM (MFP-3D, Asylum Research, Santa Barbara, 
CA) was used to characterize the morphology of the materials. The tips used in the 
measurements were made of SiN. The AFM samples were prepared by dropping diluted 
sample suspensions, which were diluted 106 times from 1mg/mL, on silicon wafers and 
nitrogen-dried before measurements. 
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Inductively Coupled Plasma Optical Emission Spectrometer: Leeman Prodigy 
inductively coupled plasma-optical emission spectroscopy (ICP-OES) was performed to 
analyze the Fe composition in the NGs (Hudson, NH). All samples were digested by aqua 
regia and diluted with water before measurements.  
Relaxivity: The r1 relaxivities of the ultrasmall Fe3O4 NPs, Fe3O4/PEI NGs and Fe3O4/PEI-
Ac NGs were measured using the 0.5T NMI20-Analyst NMR Analyzing and Imaging 
system (Shanghai Niumag Corporation, Shanghai, China). The parameters were set as 
follow: Q-IR sequence, point resolution = 156 mm  156 mm, section thickness = 0.6 mm, 
TR = 6000 ms, TE =160 ms, number of excitation = 1. The r1 relaxivity of the materials were 
calculated by a linear fitting of the inverse relaxation time as a function of the Fe 
concentration. The MR imaging of samples was performed using a 3.0T signa HDxt (GE 
CO., LTD.  Milwaukee, WI).  
 
1.8 Encapsulation of DOX within Fe3O4/PEI-Ac NGs 
 
The Fe3O4/PEI-Ac NGs (10 mg) were dispersed in 1 mL of PBS. DOX at a mass ratio of 
0.5, 1 and 2 to Fe3O4/PEI-Ac NGs was dissolved in 1 mL water, respectively. Then the 
Fe3O4/PEI-Ac NG solutions were mixed with the DOX solutions under stirring overnight. 
After that, the mixture solutions were centrifuged (13000 rpm for 15 min) in order to get the 
precipitates, washed with water for 3 times and the supernatants in each step (containing the 
non-complexed free DOX) were collected. The precipitates were redispersed in 2 mL of PBS 
and stored at 4 ℃. The supernatants were analyzed via UV-vis spectroscopy and the 
encapsulated amount of DOX in the NGs was calculated via subtraction of the initial added 
DOX amount with that in the supernatants. 
According to the standard curve of DOX in water, the drug loading content (DLC) and 
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drug loading efficiency (DLE) were calculated using the following equations, respectively: 
DLC =  
𝑚𝑙𝑜𝑎𝑑𝑖𝑛𝑔 𝑑𝑟𝑢𝑔
𝑚𝑛𝑎𝑛𝑜𝑔𝑒𝑙𝑠+𝑚𝑑𝑟𝑢𝑔
× 100%                                     (1) 
DLE =  
𝑚𝑙𝑜𝑎𝑑𝑖𝑛𝑔 𝑑𝑟𝑢𝑔
𝑚𝑛𝑎𝑛𝑜𝑔𝑒𝑙𝑠
× 100%                                        (2) 
mloading drug: the mass of the drug which was loaded in the NGs 
mdrug: the mass of the drug which was used in the reaction 
mnanogel: the mass of the NGs which were used in the reaction. 
 
1.9 In vitro drug release kinetic studies 
 
The formed Fe3O4/PEI-Ac NGs /DOX solution was diluted to have a DOX 
concentration of 1 mg/mL in phosphate buffer with different pH values. The dialysis bags 
with a MWCO of 8 000 – 14 000 were used to hold 1 mL of the diluted Fe3O4/PEI-Ac NGs 
/DOX solution. After well-sealed, the bags were immersed in 9 mL of pH = 7.4 and pH = 
5.5 phosphate buffer, respectively. All the systems were placed in a shaker at a constant 
temperature of 37 °C. At different time points, 1 mL of the outside medium was taken and 
the absorbance at 480 nm was measured using a UV-vis spectrophotometer. After that, the 
outer phase was replenished with 1 mL fresh corresponding buffer solution. Finally, the 
curve of DOX release from the Fe3O4/PEI-Ac NGs/DOX under different pH conditions in 




1.10 Cell biological evaluation 
 
In the in vitro testing, 4T1 tumor cells (a mammary carcinoma cell line from the 
mammary gland tissue of a mouse) were continuously grown in the cell culture flask with 
DMEM supplemented with 10% FBS, 100 U mL−1 penicillin, and 100 U mL−1 streptomycin. 
The culture was maintained at 37 °C in a wet incubator with 5 % CO2, and the medium was 
replaced every 3 days. 
To check if the Fe3O4/PEI-Ac NGs /DOX complex was therapeutically active, two days 
before exposure to the NGs, the cells at logarithmic growth stage were plated into 96-well 
plates at a density of 1 × 104 cells per well in supplemented DMEM. For the cytotoxicity 
experiments, the medium was then replaced with fresh DMEM (100 µL) containing free 
DOX·HCl, Fe3O4/PEI-Ac NGs or Fe3O4/PEI-Ac NGs /DOX complex with different DOX 
concentrations (2.5, 5, 10, 20, and 40 µg/mL, respectively). For the DOX-free Fe3O4/PEI-
Ac NGs, the NG concentration is equal to the Fe3O4/PEI-Ac NGs/DOX complex. In all 
cases, the samples were dissolved in PBS prior to testing. Then the cells were incubated for 
24 h at 37 °C. After treatment with DOX or Fe3O4/PEI-Ac NGs /DOX complex, cell 
morphology was observed by optical microscopy. After morphology observation, cell 
counting kit - 8 (CCK-8) assay was performed to quantify the viability of the cells. 
Furthermore, PBS was used as a control to check the therapeutic activity of the drug. 
To check the cellular uptake of the Fe3O4/PEI-Ac NGs /DOX complex, two days before 
exposure to NGs, the cells at logarithmic growth stage were plated into a glass bottom dish 
at a density of 15 × 104 cells per dish in supplemented DMEM. The next day, the medium 
was replaced with supplemented DMEM (200 µL) containing free DOX·HCl or Fe3O4/PEI-
Ac NGs /DOX complex at the same DOX concentration (10 µg/mL) and then the cells were 
incubated for 4 h at 37 °C. Only PBS was used in the control. After that, the medium was 
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dumped, the bottom of the dish was covered with glutaraldehyde (1%, v/v) for 15 min, 
washed and added of 4′,6-diamidino-2-phenylindole (DAPI, 0.1%, v/v) for cell nucleus 
staining. After 30 min, the bottom of the dish was washed with PBS to remove DAPI.  
Furthermore, to quantify the uptake of the Fe3O4/PEI-Ac NGs /DOX complex by cells, 
two days before exposure to NGs, the cells at logarithmic growth stage were plated into 12-
well plates at a density of 15 × 104 cells per well in supplemented DMEM. The next day, the 
medium was replaced with supplemented DMEM (100 µL) containing free DOX or 
Fe3O4/PEI-Ac NGs /DOX with different DOX concentrations (1.25, 2.5, 5, 10, 20, and 40 
µM) and then the cells were incubated for 4 h at 37 °C. After that, the medium was dumped 
and the cells were washed with PBS for 3 times, collected by centrifugation (1000 rpm, 
5min) and resuspended in 1 mL of PBS. All the parallel groups of cells were collected and 
redispersed for flow cytometry analysis using a BD FACS Calibur flow cytometer (Franklin, 
CA). 
 
1.11 In vivo tumor therapy and MR imaging  
 
All animal experiments were carried out after approval by the ethical committee for 
animal care of Donghua University and according to the policy of the National Ministry of 
Health (China). The female BALB/c nude mice with 4-6 weeks age were purchased from 
Shanghai Slac Laboratory Animal Center (Shanghai, China). After feeding for one week in 
a sterile animal room, 4T1 cells were injected into the right hind leg of the nude mice at a 
dose of 1.5 x 106 cells/mouse. When the tumor volume reached 0.5-1.2 cm3 (about two weeks 
after injection of tumor cells), the tumor-bearing nude mice were randomly divided into 4 
groups (control group, free DOX group, Fe3O4/PEI-Ac NGs /DOX treatment group and non-
drug-loaded Fe3O4/PEI-Ac NGs group), and each group had 5 mice. On the first day, the 
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control group, the free DOX group, the treatment group, and the non-drug-loaded group were 
intravenously injected with PBS (200 μL), free DOX (200 μL in PBS, [DOX] = 20 μg/mL), 
Fe3O4/PEI-Ac NGs/DOX complex (200 μL in PBS, [DOX] = 20 μg/mL), and Fe3O4/PEI-Ac 
NGs (NGs concentration is the same as the treatment group) for each mouse. That day was 
recorded as the first dose. The materials were administered once every 3 days for a total of 
5 doses. Tumor volume was measured every 3 days and mouse weight was weighed every 3 
days. Tumor volume and relative tumor volume were calculated using the following 




                                                    (3) 
where a and b represent the maximum and minimum diameters of the tumor, respectively. 
Relative tumor volume =
𝑉
𝑉0
                                                            (4) 
where V and V0 represent the tumor volume after administration and the tumor volume 
before administration, respectively. Thirty days after the first time of the treatment, 
representative mice were selected and sacrificed from each group, and their main organs and 
tumors were extracted.  
The Fe distribution in various organs of nude mice at different time points post injection 
of Fe3O4/PEI-Ac NGs/DOX was determined. The PBS buffer solution of Fe3O4/PEI-Ac 
NGs/DOX was injected into the nude mice through intravenous injection (Fe mass = 150 μg, 
in 200 L PBS for each mouse), and the mice were sacrificed at different time points post-
injection (0.5, 1, 12, 24 and 48 h, respectively). The organs (heart, liver, spleen, lung, kidney) 
and tumor was removed, weighed, then digested by aqua regia for 24 h. The concentration 
of Fe in the organ and tumor was measured by ICP-OES. Nude mice injected with only 0.2 
mL of PBS solution without Fe3O4/PEI-Ac NGs/DOX were used as control. The results of 
three parallel nude mice were used for each group. Parallel organ or tumor samples were 




The BALB/c nude mice were chosen to construct subcutaneous 4T1 tumor model. 
Each tumor mouse was intravenously injected with a PBS solution containing ultrasmall 
Fe3O4 NPs or Fe3O4/PEI-Ac NGs /DOX (Fe mass = 150 μg, in 200 L PBS). MR scanning 
was performed using a 3.0T signa HDxt (GE CO., LTD. Milwaukee, WI). to evaluate the 
tumor imaging performance of the materials. MR scanning parameters were set as follows: 
wrist ECHO sequence (TR = 376 ms, TE = 10 ms, point resolution = 256 mm  256 mm, 
section thickness =5 mm, and FOV = 100  100 mm).  
 
1.12 Statistical analysis 
 
One-way ANOVA statistical analysis was performed to evaluate the significance of 
the experimental data. A value of 0.05 was selected as the significance level, and the data 



























































CHAPTER 3 – RESULTS AND DISCUSSION 
 
 
2.1 Characterization of Fe3O4/PEI-Ac NGs 
 
TGA analysis. After the citrate-Fe3O4 NPs were conjugated with the PEI NGs, TGA 
was performed to confirm their composition (Figure 9). It is clear to see that the weight of 
citrate-Fe3O4 NPs and Fe3O4/PEI NGs decreases with the increase of the temperature, and 
the decrease trend of Fe3O4/PEI NGs curve is faster than citrate-Fe3O4. During the 
temperature increase from room temperature to 900 ℃, after simple mathematical 
calculation, the percentage of citrate-Fe3O4 NPs loaded within the PEI-based NGs was 
estimated to be 55.38% (w/w). 
 
Figure 9. TGA curve of citrate-Fe3O4 and Fe3O4/PEI NGs. 
 
DLS and zeta potential measurements. To decrease the amine-related cytotoxicity of the 
NGs, acetylation of the Fe3O4/PEI NGs was performed. Through the DLS and zeta-potential 
analysis of each material involved in the synthesis procedure, the hydrodynamic size and 
surface potential presented noticeable change. As shown in Table 1, the citrate-Fe3O4 NPs 
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present a negative charge before conjugation, and the PEI NGs are positively charged. After 
conjugation, the surface potential of the NGs decreases to 29.3 mV. Further acetylation of the 
NGs leads to a further decrease of the surface potential of the NGs to 13.3 mV. The increasing 
of the hydrodynamic size after each step of modification confirms the success of each 
synthesis procedure.  
 
Table 1. Hydrodynamic size and zeta potential of PEI NG, Fe3O4/PEI NGs and Fe3O4/PEI-Ac NGs. 
Sample Size (nm) PDI 
Zeta Potential 
(mV) 
Fe3O4 27.5  3.2 0.162  0.058 -37.9  1.35 
PEI NGs 180.38  5.48 0.234  0.024 38.9  0.624 
Fe3O4/PEI NGs 251.4  6.34 0.242  0.003 29.3  0.88 
Fe3O4/PEI-Ac 
NGs 
263.8  3.81 0.334  0.03 13.3  1.15 
 
Morphology characterization. AFM was used to observe the morphology of the 
synthesized NGs. As shown in Figure 10, the size of the PEI-based NGs is around 137 nm, 
and after conjugation and surface acetylation (Fe3O4/PEI-Ac NGs) the size increased to 157 
nm while maintaining the same good monodispersity. Apparently, the size of the NGs 
measured by AFM is different from that measured by DLS. This is because, in the DLS 
analysis, we got the hydrodynamic size of the materials in a swollen state, while in AFM we 
measured the size of the NGs in the dried state and the NGs shrinks. It’s worth noting that, 
different from other quasi-spherical nanomaterials, the AFM image of the NGs shows a large 
flat image, and the height was significantly different from their width, which may be caused 




Figure 10. AFM images of a) PEI NGs and b) Fe3O4/PEI-Ac NGs. 
 
r1 relaxivity characterization. Because the size of citrate-stabilized Fe3O4 NPs, which 
were synthesized by Solvothermal method, is lower than 5 nm, the formed ultrasmall Fe3O4 
NPs are well suitable for T1-weighted MR imaging
99. MR phantom studies show that both 
materials enable MR contrast enhancement in an Fe concentration-dependent manner. The 
Fe3O4/PEI-Ac NGs seem to display a higher MR signal intensity than the citrate-stabilized 
Fe3O4 NPs under the same Fe concentrations. We then measured the r1 relaxivities of the 
citrate-stabilized Fe3O4 NPs and Fe3O4/PEI-Ac NGs. As shown in Figure 11b, the r1 
relaxivity of citrate-Fe3O4 NPs was measured to be 1.15 mM
-1s-1. After the conjugation onto 
PEI-based NGs, the formed hybrid NGs show a higher r1 relaxivity (2.29 mM
-1s-1) than the 
citrate-stabilized Fe3O4 NPs. This is due to the fact that the citrate-stabilized Fe3O4 NPs, 
once entrapped within the NGs, could have a relatively longer rotational correlation time, 






Figure 11. a) Color T1-weighted MR images of the citrate-Fe3O4 NPs and Fe3O4/PEI-Ac NGs at an 
Fe concentration of 0.1, 0.2, 0.4, 0.8, and 1.6 mM, respectively. b) Linear fitting of 1/T1 as a function 
of Fe concentration for the two different materials. The color bar from red to blue indicates the 
gradual decrease of MR signal intensity. 
 
2.2 Encapsulation of DOX within the Fe3O4/PEI-Ac NGs 
 
The DOX loading efficiency and loading content within the Fe3O4/PEI-Ac NGs were 
obtained by measurement of the non-complexed free DOX in supernatant that was recovered 
by centrifugation via UV-Vis spectroscopy. First of all, we got the standard curve of DOX 




Figure 12. Standard absorption-concentration calibration curve of DOX in PBS (pH = 7.4).  
 
Secondly, we optimized ratios between DOX and Fe3O4/PEI-Ac NGs during the drug 
loading process. The Fe3O4/PEI-Ac NGs/DOX formed at different mass ratios between DOX 
and the NGs (1:2, 1:1, or 2:1) were measured by UV-vis spectrometry based on the standard 
calibration curve. As shown in Table 2, the mass ratio of DOX:NGs at 1:1 presents the best 
loading content when compared with others, while the mass ratio of 2:1 presents the greatest 
loading efficiency. According to the results, we selected the ratio of 2:1 as the optimized 
ratio for the subsequent experiment. 
 




1:2 15.3% 22.9% 
1:1 21.9% 43.9% 






2.3 In vitro release kinetic studies 
 
The in vitro release study of DOX from the Fe3O4/PEI-Ac NGs/DOX complexes was 
performed in phosphate buffer with different pH values (5.5 and 7.4) and the temperature 
was kept at 37℃. In each case, the release of DOX from the complexes showed a sustained 
release profile. The cumulative release of DOX from the Fe3O4/PEI-Ac NGs/DOX in a 
weakly acidic environment of pH = 5.5 was 44.1 ± 2.05%, which was higher than that in a 
physiological environment with pH = 7.4. This result indicates that the PEI-based NGs have 
pH-responsiveness, and DOX can be rapidly released in the slightly acidic environment 
which is similar to tumor tissue, and slow release rate and low cumulative release rate in the 
physiological environment of normal tissues. This is certainly beneficial for desired tumor 
treatment. 
 





2.4 Therapeutic efficacy of DOX encapsulated within Fe3O4/PEI-Ac NGs 
 
The therapeutic efficacy of the DOX encapsulated within the Fe3O4/PEI-Ac NGs on 
4T1 tumor cells was tested using the CCK-8 assay (Figure 14). It is clear that the cell 
viability of free DOX group is much lower than that of the Fe3O4/PEI-Ac NGs/DOX group, 
which is due to the slow release of the DOX from the NGs. In both cases, the cell viability 
decreases with the increase of DOX concentration. For the drug-free Fe3O4/PEI-Ac NGs, 
under the studied NG concentrations, the cell viability does not seem to have a significant 
change when compared to the PBS control. So, the Fe3O4/PEI-Ac NGs show good 
cytocompatibility.  
 
Figure 14. CCK-8 assay of 4T1 cell viability after they were treated with Fe3O4/PEI-Ac NGs/DOX, 
free DOX and Fe3O4/PEI-Ac NGs at different DOX or NG concentrations for 24 h. The 4T1 cells 
treated with PBS were used as a control. 
 
2.5 Cellular uptake of the Fe3O4/PEI-Ac NGs/DOX complex 
 
To check the cellular uptake of DOX-loaded NGs, confocal laser scanning microscopy 
and flow cytometry were performed. After DAPI staining, PBS group just shows the blue 
fluorescence of the nuclei stained by DAPI (As shown in Figure 15). The free DOX group 
shows the blue fluorescence from DAPI and the red fluorescence from DOX. After merging 
those two, the cells from free DOX group showed purple nuclei and red cytoplasm, the 
purple of the nuclei is caused by the mixture of red and blue. This implies that free DOX is 
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able to enter to the cell nuclei. For the group of Fe3O4/PEI-Ac NGs/DOX, obvious blue and 
red fluorescence can also be seen, but the majority of DOX-associated red fluorescence 
appears in the cytoplasm, not in the cell nuclei. This implies that DOX was released from 
the NGs before getting into the cell nuclei, which takes time. 
 
Figure 15. Confocal microscopic images of 4T1 cells after treatment for 4 h with the free DOX and 
Fe3O4/PEI-Ac NGs/DOX at a DOX concentration of 10 μg/mL. The 4T1 cells treated with PBS were 
used as a control. 
 
Flow cytometry analysis was further used to confirm the cellular uptake of the DOX-
loaded NGs (Figure 16). The right shifted histogram shown in the left panel of Figure 16 
indicate that the cells are able to take up the NGs to display DOX-associated fluorescence 
signal. With the increase of DOX concentration, the cell fluorescence histogram displays 
more apparent right shift trend, indicating that there are more NGs uptaken by cells. This 
trend can be further proven by plotting the mean fluorescence of cells as a function of DOX 






Figure 16. Flow cytometric analysis of 4T1 cells treated with Fe3O4/PEI-Ac NGs/DOX at different 
DOX concentrations for 4 h. The 4T1 cells treated with PBS were used as a control. In the right 
panel, the mean fluorescence of cells treated with Fe3O4/PEI-Ac NGs/DOX as a function of DOX 
concentration is shown. 
 
To further confirm the NG uptake by cells, we examined the cellular Fe uptake by ICP-
OES. After 4T1 cells were treated with the Fe3O4/PEI-Ac NGs/DOX at different DOX 
concentrations for 24 h, the 4T1 cells were digested by aqua regia and subjected to ICP-OES 
assay (Figure 17). Obviously, the cellular Fe uptake of Fe3O4/PEI-Ac NGs /DOX increases 
with the increase of the concentration of DOX, which is consistent with the results obtained 
from confocal laser scanning microscopy and flow cytometry analysis. 
 
Figure 17. Fe uptake in the 4T1 cells treated with the Fe3O4/PEI-Ac NGs/DOX at different DOX 
concentrations for 24 h. The 4T1 cells treated with PBS were used as a control. 
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2.6 In vivo antitumor therapy and MR imaging of tumors  
 
Antitumor effect in vivo. The processes of the in vivo treatment are shown in Figure 
18 a. As shown in Figure 18 b, after drug administration for 30 days, the survival rate of 
PBS and drug-free Fe3O4/PEI-Ac NGs groups was only 40%, while those of free DOX group 
and Fe3O4/PEI-Ac NGs/DOX group were 60% and 80%, respectively. Accordingly, the 
survival time of mice in the free DOX group and Fe3O4/PEI-Ac NGs/DOX group could be 
prolonged. In Figure 18c, both groups of free DOX and Fe3O4/PEI-Ac NGs/DOX (treatment 
group) have a relatively small tumor volume change, and the Fe3O4/PEI-Ac NGs/DOX group 
has a better tumor inhibition effect than free DOX group. On the contrary, the drug-free 
Fe3O4/PEI-Ac NGs group exhibits the same tumor growth trend as the PBS. In any case, the 
4 groups show the same body weight change with slightly increasing trend after 15 days of 
treatment (as shown in Figure 18d). This means that all the treatments do not exert systemic 
toxicity to the tumor-bearing mice. 
 
Figure 18. Antitumor therapy in vivo. (a) Schematic diagram of the treatment process of the tumor-
bearing mice in vivo. (b) Survival rate of the mice in each group during 30 days treatment. (c) Relative 
tumor volume and (d) Body weight of mice after different treatments for 15 days. 
 
Biodistribution of Fe element. We measured the Fe distribution of the NGs in major 
organs and tumor at different time points post administration. As shown in Figure 19, 
Fe3O4/PEI-Ac NGs/DOX are mainly cleared by spleen, lung and kidney. The Fe content 
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dramatically increases in these organs after administration and rises to the maximum at 1 h 
post injection. Then the Fe content decreases gradually. After 48 h of administration, the Fe 
content material in each major organ was very small. This indicates that the Fe3O4/PEI-Ac 
NGs/DOX can be gradually metabolized in vivo and have good in vivo biocompatibility. 
 
Figure 19. The Fe biodistribution in major organs and tumor of the mice at different time points post 
injection of the Fe3O4/PEI-Ac NGs/DOX (Fe mass = 150 μg, in 0.2 mL PBS for each mouse). 
 
H&E staining. As shown in Figure 20, the injection of the Fe3O4/PEI-Ac NGs/DOX 
does not seem to cause any significant damages to major organs of mice, and there is no 
significant change in organ morphology when compared with the control group. This 
indicates that the developed Fe3O4/PEI-Ac NGs/DOX do not influence the major organs of 




Figure 20. Representative H&E staining of the sections of the heart, liver, spleen, lung and kidney after 
each tumor-bearing mouse was treated with PBS, free DOX, Fe3O4/PEI-Ac NGs/DOX and Fe3O4/PEI-
Ac NGs complexes for 30 days. 
 
TUNEL staining. As shown in Figure 21, the green part represents the apoptotic cells, 
and the blue part represents the cell nucleus. The TUNEL staining results of free DOX and 
Fe3O4/PEI-Ac NGs/DOX groups reveal that these two materials cause massive apoptosis of 
tumor cells, which is significantly different from the PBS group and drug-free Fe3O4/PEI-
Ac NGs group. 
 
  
Figure 21. Representative TUNEL staining of tumor sections after the treatment with PBS, free 
DOX, Fe3O4/PEI-Ac NGs/DOX and Fe3O4/PEI-Ac NGs complexes, respectively for 30 days. 
 
MR imaging of tumors. As shown in Figure 22, compared with the blank group before 
injection, the tumor MR signal intensity increases after the injection of the PBS solution of 
Fe3O4/PEI-Ac NGs/DOX and ultrasmall Fe3O4 NPs (Figure 22 a). This suggests that 
ultrasmall Fe3O4 NPs and Fe3O4/PEI-Ac NGs/DOX can be enriched and presented in the 
tumor site with blood circulation after intravenous injection. In particular, the injection of 
Fe3O4/PEI-Ac NGs/DOX leads to the gradual enhancement of tumor MR signal and the 
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tumor MR signal reaches the peak value at 30 min post injection. After 30 min, the tumor 
MR signal intensity slowly declines, and the MR signal can be maintained for at least 75 
min. By quantitatively analyzing the MR signal to noise ratio (SNR), we show that the tumor 
MR SNR for the NG group is much larger than that for the ultrasmall Fe3O4 NP group at the 
same time points post injection (Figure 22 b). This means that the Fe3O4/PEI-Ac NGs/DOX 
display a better MR imaging performance than the ultrasmall Fe3O4 NPs, possibly due to the 
better r1 relaxivity of the NGs.   
 
Figure 22. In vivo T1-weighted MR images (a) and signal to noise ratio (b) of xenograft 4T1 tumors 
before and at different time points post intravenous injection of the ultrasmall Fe3O4 NPs or the 






























































CHAPTER 4 – GENERAL CONCLUSIONS 
 
In this study, we developed a unique method to generate hybrid PEI-based NGs modified 
with ultrasmall Fe3O4 NPs and loaded with anticancer drug DOX for theranostics of tumors. 
Through the rational design and precise synthesis of hybrid NGs, both imaging agents of 
ultrasmall Fe3O4 NPs and anticancer drug DOX can be loaded within a single PEI-based 
platform for MR imaging-guided chemotherapy of tumors. The hybrid NGs presented double 
r1 relaxivity times when compared with ultra-small iron oxide without NGs. It is a significant 
improvement of the T1 contrast agents, which is caused by the PEI-based NGs that are able 
to improve the dispersiveness of the ultra-small iron oxide, making them more stable and not 
easily aggregated. After loading with DOX, the hybrid NGs presented different release rates 
under different pH conditions. In the acidic environment, which has a pH value similar to 
the tumor organ, the hybrid NGs showed better performance. In this study, 4T1 cells and the 
xenografted 4T1 tumors were used as models to study the performance of the hybrid NGs. 
We show that the MR imaging capability of the hybrid NGs is significantly enhanced, and 
the tumor suppression effect of the hybrid NGs is significantly improved. Such development 
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